drugset / Trial / NCT06956092

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

NCT06956092

Phase 4 Not yet recruiting 40 enrolled Zhengzhou University
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are: * Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving Glofitamab treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive Glofitamab treatment as per the instructions in the package insert. * Visit the clinic as instructed for checkups and tests.

Timeline

Start
2025-05-30
Primary completion
2028-06
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Glofitamab Monoclonal antibody

Indications